Tyra Biosciences Launches Underwritten Offering with Pre-Funded Warrants to Fund Dabogratinib 3x3 Strategy
TYRA sits 85% above its 52-week low of $11.703 on elevated volume (1.8× avg).
Summary
Tyra Biosciences filed a free writing prospectus for an underwritten offering of common stock and pre-funded warrants, with proceeds directed to its dabogratinib 3x3 development strategy. Specific share counts and pricing are not yet disclosed.
Key Events · Financing and Capital Events · TYRA
-
Underwritten Offering Launched
Tyra Biosciences filed an FWP for an underwritten offering of common stock and pre-funded warrants, supplementing the S-3ASR shelf filed the same day. Share count and offering price are not yet disclosed.
-
Pre-Funded Warrants Added
The offering includes pre-funded warrants with a $0.001 exercise price, exercisable until fully exercised, subject to 4.99% (up to 19.99%) beneficial ownership limitations. No public trading market is expected for the warrants.
-
Underwriting Syndicate Named
Jefferies, Guggenheim, Cantor, Barclays, and William Blair are joint book-running managers; Wedbush, Raymond James, and Oppenheimer are lead managers.
-
Proceeds for Dabogratinib 3x3
Net proceeds will fund the dabogratinib 3x3 development strategy in LG-UTUC, IR NMIBC, and ACH, plus preclinical programs and working capital.
Analysis · TYRA · Life Sciences
Just days after reporting positive Phase 2 SURF302 data for oral dabogratinib in bladder cancer, Tyra Biosciences is launching a specific underwritten offering of common stock and pre-funded warrants. The offering adds a new layer of dilution on top of the existing $250 million ATM program, but the proceeds are earmarked for advancing the 'dabogratinib 3x3' development strategy across three indications. The pre-funded warrants carry a nominal $0.001 exercise price and 4.99%/19.99% ownership blockers, and the deal is being led by a syndicate of five joint book-running managers — a sign of institutional demand for the raise. The filing does not disclose the number of shares or the offering price, so the exact dilution and proceeds remain unknown until the pricing supplement is filed.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TYRA was trading at $21.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $11.70 to $40.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.